J. Peter KLEIN et al. Appl. No. 09/544,984 September 10, 2004 Atty. Docket No.: 4377-38

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Claims 1-9 (Canceled)

Ok to enter

10. (Original) A compound having the formula

11/10/04

or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A compound having the formula

or a pharmaceutically acceptable salt thereof..

## Claims 12-17 (Canceled)

18. (Currently Amended) A pharmaceutical composition comprising the compound as defined in any of claims 8-15 10, 11 or 47-49, in which the compound is an in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.

## Claims 19-46 (Canceled)

47. (Previously Presented) A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula (I):

J. Peter KLEIN et al. Appl. No. 09/544,984 September 10, 2004

17:08

Atty. Docket No.: 4377-38

wherein:

X is N(R<sub>3</sub>), Y is NH or N(CH<sub>3</sub>) and Z is C(R<sub>4</sub>), where R<sub>3</sub> is H, CH<sub>3</sub> or CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, and R<sub>4</sub> is selected from the group consisting of  $C_{(1-20)}$ alkylamino,  $C_{(1-20)}$ alkylaminoalkyl,  $C_{(1-20)}$ aminoalkyl,  $C_{(1-20)}$ aminoalkoxyalkenyl,  $C_{(1-20)}$ aminoalkyl,  $C_{(1-20)}$ tetraaminoalkyl,  $C_{(5-15)}$ aminotrialkoxyamino,  $C_{(1-20)}$ alkylamido,  $C_{(1-20)}$ alkylamidoalkyl,  $C_{(1-20)}$ amidoalkyl,  $C_{(1-20)}$ acetamidoalkyl;

R<sub>1</sub> is -(CH<sub>2</sub>)<sub>n</sub>-CHOH-CH<sub>3</sub> which may be substituted with a member of the group consisting of acylamino and -NR<sup>a</sup>R<sup>b</sup>, wherein each of R<sup>a</sup> and R<sup>b</sup> may be the same or different and each is selected from the group consisting of hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclic group; and n is 3-7; and

R<sub>2</sub> is hydrogen or methyl.

- 48. (Previously Presented) The therapeutic compound of claim 47 wherein  $R_1$  is  $-(CH_2)_{n}$ -CHOH-CH<sub>3</sub>, X is N(CH<sub>3</sub>), Y is NH, and  $R_4$  is  $C_{(1-20)}$ alkylaminoalkyl.
- 49. (Previously Presented) The therapeutic compound of claim 47 wherein R<sub>1</sub> is -(CH<sub>2</sub>)<sub>n</sub>-CHOH-CH<sub>3</sub> which the hydroxy group is substituted with -NR<sup>a</sup>R<sup>b</sup>, wherein each of R<sup>a</sup> and R<sup>b</sup> may be the same or different and each is selected from the group consisting of hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclic group, X is N(CH<sub>3</sub>), Y is NH, and R<sub>4</sub> is hydrogen.